Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:03:42 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:STRO from 2023-05-04 to 2024-05-03 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 08:00U:STRONews ReleaseSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRalphaME-O1 Trial
2024-04-02 06:19U:STRONews ReleaseSutro Biopharma Announces Pricing of $75 Million Underwritten Offering
2024-03-25 16:30U:STRONews ReleaseSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2024-02-06 16:05U:STRONews ReleaseSutro Biopharma to Participate in Upcoming Investor Conferences
2024-01-04 16:05U:STRONews ReleaseSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR Ž ±-targeting ADC
2023-12-14 16:05U:STRONews ReleaseSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR Ž ±-targeted ADC, on January 4, 2024
2023-12-11 16:05U:STRONews ReleaseSutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
2023-12-04 16:05U:STRONews ReleaseSutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
2023-11-27 16:00U:STRONews ReleaseVaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
2023-11-21 16:05U:STRONews ReleaseSutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
2023-11-13 16:30U:STRONews ReleaseSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-10-22 04:25U:STRONews ReleaseSutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
2023-10-16 16:05U:STRONews ReleaseSutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
2023-09-19 08:00U:STRONews ReleaseSutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
2023-08-30 08:00U:STRONews ReleaseSutro Biopharma to Participate in Upcoming Investor Conferences
2023-08-10 16:30U:STRONews ReleaseSutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-06-26 08:00U:STRONews ReleaseSutro Biopharma and Blackstone Announce Royalty Financing Collaboration
2023-06-03 16:00U:STRONews ReleaseSutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
2023-05-31 08:00U:STRONews ReleaseSutro Biopharma to Participate in the Jefferies Healthcare Conference
2023-05-15 08:00U:STRONews ReleaseSutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-05-08 08:00U:STRONews ReleaseSutro Biopharma to Present at the JMP Securities Life Sciences Conference